Cardiac Syndrome X Does Not Benefit From Allopurinol

Share this content:
The researchers found that allopurinol significantly reduced serum uric acid levels vs placebo.
The researchers found that allopurinol significantly reduced serum uric acid levels vs placebo.

HealthDay News — Allopurinol does not appear to improve exercise capacity or peripheral endothelial or coronary function in patients with cardiac syndrome X, according to a study published in Cardiovascular Therapeutics.

Tiong Keng Lim, MD, from National Heart Centre Singapore, and colleagues randomized 19 patients with cardiac syndrome X (mean age 59 years) to 6 weeks of treatment with either allopurinol (600mg/day) or placebo. Patients were crossed over to the other study arm after a 4-week washout period.

The researchers found that allopurinol significantly reduced serum uric acid levels vs placebo. 

There was no significant difference in maximum exercise time, coronary flow reserve, or flow-mediated vasodilatation of the brachial artery between the allopurinol and placebo groups. However, there was a trend toward allopurinol reducing serum B-type natriuretic peptide compared with placebo (P = .07).

"In patients with cardiac syndrome X, high dose allopurinol did not improve exercise capacity, coronary or peripheral endothelial function," conclude the authors.

Reference

Lim TK, Noman A, Choy AMJ, et al. The APEX trial: Effects of allopurinol on exercise capacity, coronary and peripheral endothelial function, and natriuretic peptides in patients with cardiac syndrome X [published online November 26, 2017]. Cardiovasc Ther. doi: 10.1111/1755-5922.12311

You must be a registered member of The Cardiology Advisor to post a comment.

Sign Up for Free e-Newsletters